BioVoice News April 2017 Issue 11 Volume 1 | Page 17

The Indian biotechnology industry has set on its biggest mission ever. And it is to scale up itself to a big $100 billion sector by 2025. Policymakers dealing with the subject are hopeful of achieving the target while citing the number of programs that have been launched by government. One may question them on implementation but of course the intent is clearly visible in their enthusiasm and energy. However, it goes without saying that while there are opportunities and efforts to tap them, there are roadblocks too in the way. Whether we are doing enough on the ground to reach this set goal is the question one may ask at the outset. Let’s look at the current situation. India is the twelfth-largest biotechnology market in the world with a 2 percent share of the global market. It ranks third in Asia Pacific region after Japan and China. As per the BioVoice’s own estimates, the Indian biotech industry is expected to have grown approximately to be a $8 billion sector during 2016-17, at a growth rate of close to 12 percent. However, according to a special report prepared by the Association of Biotechnology-Led Enterprises (ABLE), the India’s fast-growing bio- economy has crossed the $35.1 billion in 2015. The difference between figures is due to the wider inclusion of agriculture, startups and services sector in the latter. sector dominated the industry, accounting for 57 percent share of the companies formed followed by bioresearch (16%), agribiotech (10%), and bioindustrial (9%). Overall nearly 40 percent of the companies were involved in the manufacture of products and ingredients. About 16 percent start-ups were each into medical health instruments/ appliances and R&D services respectively. Now coming to the startup ecosystem, we again refer to the ABLE’s latest report that suggested that there are 1022 new startups related to biosciences that have come up in the country. It mentioned that over $2.8 billion (Rs 18,700 crore) investments have happened in five years from 2012 to 2016. According to the study, private equity investments into these companies totaled around $2.6 billion and the balance came from own investments, government grants, and others like HNIs. Year 2015 was the best one attracting $851 million. The biopharma Bangalore is the biotech start-up capital of India hosting 190 of the 1022 biotech start-ups formed in the last five years. National Capital Region (NCR) ranks second with 164 startups followed closely by Mumbai (163) and Hyderabad (160). Of the 1022 new start-ups, 104 were formed in 2016; 367 during 2014 and 2015. Another 551 companies were established between the years 2012 and 2014. “This is good news and we are aiming to double this number with the ABLE Start-Ups 2020 initiative to take the count to 2020 companies by the year BIOVOICENEWS.COM 17